Stock comparison
Evercore
Generate Biomedicines
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EVR
Evercore
Market cap
$13.39B
Sector
Financials
GENB
Generate Biomedicines
Market cap
$1.86B
Sector
Financials
Overall winner
Generate Biomedicines GENB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EVR | GENB | Winner |
|---|---|---|---|
| Warren Buffett | 71B | 52D | EVR |
| Benjamin Graham | 74B | 44D | EVR |
| Philip Fisher | 49D | 78B | GENB |
| Peter Lynch | 26F | 100A | GENB |
| Joel Greenblatt | 45D | 4F | EVR |
| Charlie Munger | 69C | 77D | GENB |
| Terry Smith | 66B | 79B | GENB |
Side-by-side metrics
| Metric | EVR | GENB |
|---|---|---|
| Market cap | $13.39B | $1.86B |
| P/E (TTM) | 17.4x | - |
| EV/EBIT | 16.1x | - |
| ROIC (TTM) | 20.1% | -89.38% |
| Gross margin | 98.95% | 100.0% |
| Net margin | 16.3% | -6.37% |
| Revenue CAGR 5y | 4.08% | 55.89% |
| EPS CAGR 5y | -4.63% | - |
| Debt / Equity | 0.6x | - |
| Dividend yield | 1.01% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EVR leads on
- ROIC (TTM)20.1%vs -89.38%+122%
- Net margin16.3%vs -6.37%+103%
- Dividend yield1.01%vs 0.0%+100%
- Market cap$13.39Bvs $1.86B+86%
GENB leads on
- EV/EBIT-vs 16.1x+153%
- P/E (TTM)-vs 17.4x+123%
- Debt / Equity-vs 0.6x+118%
- Revenue CAGR 5y55.89%vs 4.08%+93%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.